West Pharmaceutical Services, Inc. (WST) saw a price drop of $5.31, representing a decrease of 1.76% from the previous close. The trading volume reached $165,723, which is 16.82% relative to the average.
During the latest quarterly earnings report on Wednesday, April 22nd, WST had a consensus estimated EPS of 1.68.
The company's forward dividend yield stands at 0.296%, with a dividend per share of 22 cents on a quarterly basis. Year-over-year, the dividend per share has increased to 75.4098 cents.
Citigroup, on April 24th, maintained a 'Buy' rating for WST, with the price at $306.36. The recent action advised holding the asset.
West Pharmaceutical Services, Inc. reported a free cash flow of $47.2 million and a net change in cash of -$269.9 million.
The company generated revenue of $844.9 million, resulting in a gross profit of $296.4 million. The net income was $138.8 million, with an EPS of $1.93.
Key ratios include a net profit margin of 16.43%, return on assets of 3.38%, and a price-to-earnings ratio of 32.5.
With total assets of $4.11 billion and total liabilities of $1.12 billion, WST holds a strong financial position.
This comprehensive analysis provides insights into the current financial status of West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.